IN2012DN01449A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01449A
IN2012DN01449A IN1449DEN2012A IN2012DN01449A IN 2012DN01449 A IN2012DN01449 A IN 2012DN01449A IN 1449DEN2012 A IN1449DEN2012 A IN 1449DEN2012A IN 2012DN01449 A IN2012DN01449 A IN 2012DN01449A
Authority
IN
India
Prior art keywords
diagnostic
blood vessels
conditions associated
pathological conditions
cancerous tissue
Prior art date
Application number
Other languages
English (en)
Inventor
Luisa Petersen Anncatrine
Hedengran Rasmussen Palle
Rosager Henriksen Jonas
Kjær Andreas
Lars Andresen Thomas
Original Assignee
Univ Denmark Tech Dtu
Rigshospitalet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Denmark Tech Dtu, Rigshospitalet filed Critical Univ Denmark Tech Dtu
Publication of IN2012DN01449A publication Critical patent/IN2012DN01449A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/025—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus inorganic Tc complexes or compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1234—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
IN1449DEN2012 2009-07-17 2010-07-16 IN2012DN01449A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200900879 2009-07-17
US30078210P 2010-02-02 2010-02-02
EP10152394 2010-02-02
PCT/DK2010/050192 WO2011006510A1 (fr) 2009-07-17 2010-07-16 Technique de chargement pour préparer des liposomes contenant des radionucléide et ionophores et dans lesquels l'ionophore est la 2-hydroxyquionoléine (carbostyrile) ou des 2-hydroxyquinoléines structurellement reliées

Publications (1)

Publication Number Publication Date
IN2012DN01449A true IN2012DN01449A (fr) 2015-06-05

Family

ID=43448962

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1449DEN2012 IN2012DN01449A (fr) 2009-07-17 2010-07-16

Country Status (7)

Country Link
US (2) US8920775B2 (fr)
EP (1) EP2453927B1 (fr)
JP (1) JP5872466B2 (fr)
AU (1) AU2010272957B2 (fr)
CA (1) CA2768444A1 (fr)
IN (1) IN2012DN01449A (fr)
WO (1) WO2011006510A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013014735A2 (pt) 2010-12-14 2016-10-04 Rigshospitalet captura de radionuclídeos em composições de nanopartículas
AU2013249307B2 (en) * 2012-04-17 2017-11-09 Merrimack Pharmaceuticals, Inc. Compositions and methods for non-invasive imaging
WO2014081655A1 (fr) * 2012-11-21 2014-05-30 Serene Oncology, Llc Composés de liaison de récepteur somatostatine comprenant l'isotope de l'etain 117m
ES2820734T3 (es) 2013-03-11 2021-04-22 Univ Wayne State Liposomas que comprenden criptandos de europio y su uso
US10781178B2 (en) 2015-08-12 2020-09-22 The General Hospital Corporation 8-hydroxyquinoline derivatives as diagnostic and therapeutic agents
AU2017229232B2 (en) * 2016-03-07 2022-12-15 Memorial Sloan Kettering Cancer Center Bone marrow-, reticuloendothelial system-, and/or lymph node-targeted radiolabeled liposomes and methods of their diagnostic and therapeutic use
WO2020055929A1 (fr) * 2018-09-11 2020-03-19 Memorial Sloan Kettering Cancer Center Liposomes radiomarqués ciblés sur la moelle osseuse, le système réticulo-endothélial et/ou les nœuds lymphoïdes et méthodes de diagnostic associées et usage thérapeutique
US11478493B2 (en) * 2019-03-08 2022-10-25 University Of South Carolina Fabrication and application of a hetero-targeted nano-cocktail with traceless linkers
WO2023240135A2 (fr) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. Chélateurs et conjugués bifonctionnels

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE88642T1 (de) 1987-11-04 1993-05-15 Vestar Inc Zusammensetzung und verfahren zur anwendung von in liposomen eingeschlossenen verbindungen in der neutroneneinfangtherapie von tumoren.
US5688488A (en) 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5525232A (en) * 1990-03-02 1996-06-11 The Liposome Company, Inc. Method for entrapment of cationic species in lemellar vesicles
JPH075561B2 (ja) * 1991-12-17 1995-01-25 工業技術院長 α−アミノ酸のジアミド誘導体
US5837282A (en) * 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US5945502A (en) * 1997-11-13 1999-08-31 Xerox Corporation Electroluminescent polymer compositions and processes thereof
NO312708B1 (no) 2000-02-21 2002-06-24 Anticancer Therapeutic Inv Sa Radioaktive liposomer til terapi
DE10012782A1 (de) * 2000-03-16 2001-09-20 Boellhoff Gmbh Verbindungsanordnung zum Anbringen eines Befestigungselementes an einem Bauteil
WO2004082626A2 (fr) * 2003-03-18 2004-09-30 Ethicon, Inc. Diagnostic et traitement faisant appel a un inhibiteur de l'aromatase
EP1616182A4 (fr) 2003-03-18 2008-04-16 Ethicon Inc Enzymotherapie de remplacement avec la 17-beta-hydroxysteroide deshydrogenase de type 2
WO2006021008A2 (fr) 2004-08-20 2006-02-23 Lind Stuart E Ionophores utilises comme agents de chimiotherapie anticancereux
CN101072588B (zh) * 2004-10-06 2012-11-28 不列颠哥伦比亚抗癌机构 用于治疗癌症的具有改善的药物保留的脂质体
GB0423565D0 (en) * 2004-10-22 2004-11-24 Algeta As Formulation
ITMI20050328A1 (it) 2005-03-03 2006-09-04 Univ Degli Studi Milano Composti peptidomimetrici e preparazione di derivati biologicamente attivi
JP2009534309A (ja) * 2006-03-31 2009-09-24 マサチューセッツ インスティテュート オブ テクノロジー 治療剤の標的化送達のためのシステム
TW200922630A (en) * 2007-09-26 2009-06-01 Nat Health Research Institutes Liposome compositions useful for tumor imaging and treatment
WO2009140215A2 (fr) * 2008-05-11 2009-11-19 Geraghty, Erin Procédé pour traiter des infections bactériennes résistant au médicament et d'autres infections par du clioquinol, de la phanquinone et des composés apparentés
CA2852564A1 (fr) * 2011-10-31 2013-05-10 Mallinckrodt Llc Compositions liposomales combinatoires pour le traitement du cancer

Also Published As

Publication number Publication date
JP5872466B2 (ja) 2016-03-01
US8920775B2 (en) 2014-12-30
EP2453927A1 (fr) 2012-05-23
US20150202336A1 (en) 2015-07-23
EP2453927A4 (fr) 2013-01-23
WO2011006510A1 (fr) 2011-01-20
CA2768444A1 (fr) 2011-01-20
AU2010272957A1 (en) 2012-03-08
EP2453927B1 (fr) 2019-05-15
AU2010272957B2 (en) 2016-03-03
US20120213698A1 (en) 2012-08-23
JP2012533523A (ja) 2012-12-27

Similar Documents

Publication Publication Date Title
IN2012DN01449A (fr)
Caudell et al. The future of personalised radiotherapy for head and neck cancer
Castaldi et al. Can “early” and “late” 18F-FDG PET–CT be used as prognostic factors for the clinical outcome of patients with locally advanced head and neck cancer treated with radio-chemotherapy?
WO2008008483A3 (fr) Compositions basées sur dendrimères et procédés d'utilisation correspondants
WO2009009203A3 (fr) Compositions à base de dendrimères et procédés pour les utiliser
WO2010120905A3 (fr) Nouvelles nanosondes pour l'imagerie moléculaire et thérapie ciblée des maladies
NZ605674A (en) X-ray imaging at low contrast agent concentrations and/or low dose radiation
WO2014205555A8 (fr) Procédés et utilisations pour diagnostiquer et traiter le cancer de la prostate
EP3208615A3 (fr) Utilisations d'inhibiteurs de hsp90 marqués
MX2015001716A (es) Niclosamida para el tratamiento de tumores solidos.
NZ710436A (en) Biospecific agents for bone
WO2009103741A3 (fr) Utilisation de ligands des récepteurs de la fsh pour diagnostiquer et traiter le cancer
Li et al. Pre-treatment metabolic tumor volume and total lesion glycolysis are useful prognostic factors for esophageal squamous cell cancer patients
WO2012109466A3 (fr) Arn long non codant spry4-it1 comme agent de diagnostic et thérapeutique
WO2015158652A8 (fr) Nouveaux biomarqueurs du cancer du sein métastatique
CO6382138A2 (es) N-cadherina: blanco para diagnosis y terapia de cáncer
GB201121914D0 (en) Method for patient selection
De Waele et al. Response assessment of hormonal therapy in prostate cancer by [11C] choline PET/CT
Demirci et al. The nodal standard uptake value (SUV) as a prognostic factor in head and neck squamous cell cancer
MX2008016493A (es) Metodo para la deteccion de diagnostico de cancer que implica cebadores y sondas para la deteccion especifica del marcador mage-3.
UA56157U (ru) Способ предоставления помощи больным с пост-травматической отоликвореей в остром периоде черепно-мозговой травмы при переломах височной кости
UA60606U (ru) Способ стереотаксической биопсии очаговых образований головного мозга глубинной локализации
MX336321B (es) 99mtc-tat-bombesina como un nuevo radiofarmaco para la deteccion temprana de cancer de mama.
Emmett et al. Imaging for melanoma and non-melanoma skin cancers
Jung et al. False-positive F-18 FDG PET/CT from foreign body reaction on anterior chest wall after endoscopic total thyroidectomy via axillo-breast approach for thyroid cancer: two case reports